A surview of recent patents on anti-infective therapy for Clostridium difficile.

Germine S Soliman, Bechoi Saleib, Stephen J Scholand

Journal: Recent patents on anti-infective drug discovery 2014;8(2):139-49

PMID: 23879822

Abstract

Clostridium difficile has become the most common infectious cause of healthcare-associated diarrhea, with serious morbidity, prolonged hospitalization and even death. Treatment of the disease utilizing today's therapies does not guarantee a successful outcome. In the past decade, many new ideas and inventions have surfaced exploring different treatment strategies of Clostridium difficile associated diarrhea (CDAD). These treatments include antitoxins, novel antimicrobials, immunoglobulins and large inert synthetic compounds. In this paper, we survey of a number of representative patents issued from 2000 to the present targeting treatment of this difficult and dreaded disease.

Address: St. Mary's Hospital Department of Internal Medicine, 56 Franklin Street, Waterbury, CT 06706, USA. [email protected]

DOI: 10.2174/1574891x113089990016

Link outs

Free resources

Medical:

https://medlineplus.gov/antibiotics.html

Other Literature Sources:

https://scite.ai/reports/23879822

Miscellaneous:

https://assays.cancer.gov/CPTAC-68

Subscription / membership required

Full Text Sources:

MeSH Terms: Anti-Bacterial Agents, Antibodies, Monoclonal, Antitoxins, Bacterial Vaccines, Bacteriocins, Clostridioides difficile, Diarrhea, Enterocolitis, Pseudomembranous, Feces, Humans, Hypothalamic Hormones, Immunoglobulins, Melanins, Molecular Targeted Therapy, Patents as Topic, Pituitary Hormones, Probiotics